Skip to main content

Spasticity News (Page 3)

Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older

BASKING RIDGE, N.J., Aug. 1, 2016 /PRNewswire/ – Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Multiple Sclerosis

Related drug support groups

tizanidine, baclofen, Zanaflex